| Name | Title | Contact Details |
|---|
Outer Cape Health Services -Wellfleet Health Center is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Wellfleet, MA. To find more information about Outer Cape Health Services -Wellfleet Health Center, please visit www.outercape.org
Cedarhurst Senior Living is a company that operates Independent Living, Assisted Living, Personal Care, and Memory Care communities under the Cedarhurst Senior Living, Cedar Ridge and Cedar Creek brands.
The Mighty is a digital health community created to empower and connect people facing health challenges and disabilities. We have over 2.5 million registered users and are adding a new one every 20 seconds. Our stories and videos are viewed and shared more than 90 million times a month. But those are just stats. This experience from a community member is what we`re really after: “How is it that I read an essay on The Mighty and it is the only place in the world where I feel truly understood? Time and time again you speak to me through your contributors. I read this headline and it could have come from my very lips…I wanted to say thank you – words can never express how truly grateful I am to the author for sharing her story, for all Mighty contributors, and to The Mighty itself. You have changed my life. I have made a close friend who lives many miles away because of our shared pain. I gain insight everyday and I finally, finally do not feel so alone in this world. Thank you. Bless you!”
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
gloStream Inc. is a Troy, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.